Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario 12 de Octubre (241)

2024

  1. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

    Journal of Thoracic Oncology, Vol. 19, Núm. 2, pp. 285-296

  2. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204

  3. Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 180-191

  4. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial

    Lung Cancer, Vol. 189

  5. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

    The Lancet Regional Health - Europe, Vol. 38

  6. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

  7. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

    Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326

  8. Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 985-990

  9. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 2

  10. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases

    Lung Cancer, Vol. 188

  11. QIM24-189: Molecular Tumor Boards Excellence. Phase 1-State of the Art in Spain

    Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

  12. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

  13. Sotorasib in KRASG12C mutated lung cancer – Authors' reply

    The Lancet

  14. Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments

    Drugs

  15. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

2023

  1. A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma

    Translational Lung Cancer Research, Vol. 12, Núm. 7, pp. 1549-1562

  2. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

    New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2039-2051

  3. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

    JTO Clinical and Research Reports, Vol. 4, Núm. 1

  4. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

    Journal of Thoracic Oncology, Vol. 18, Núm. 12, pp. 1731-1742

  5. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86